| scholarly article | Q13442814 |
| case report | Q2782326 |
| P50 | author | Jedd D. Wolchok | Q88137705 |
| P2093 | author name string | Paul B Chapman | |
| Michael A Postow | |||
| Matthew D Hellmann | |||
| Chrisann Kyi | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective | Q28388806 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma | Q37333645 | ||
| Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 | ||
| P921 | main subject | opportunistic infection | Q835718 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 19 | |
| P577 | publication date | 2014-06-18 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Opportunistic infections in patients treated with immunotherapy for cancer | |
| P478 | volume | 2 |
| Q92061847 | A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab |
| Q47349715 | Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab |
| Q37369239 | Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities |
| Q42369857 | Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. |
| Q38577834 | Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade |
| Q50086043 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat |
| Q90454353 | Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors |
| Q26830509 | Immune Checkpoint Blockade in Cancer Therapy |
| Q47928843 | Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. |
| Q36173638 | Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. |
| Q40959994 | Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. |
| Q56890147 | Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature |
| Q90600864 | Invasive fungal infections in high-risk patients: report from TIMM-8 2017 |
| Q34545316 | Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. |
| Q50015039 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. |
| Q31034415 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper |
| Q38930084 | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| Q34667977 | PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma |
| Q48155956 | Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). |
| Q93103947 | Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations |
| Q38870763 | Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. |
| Q36710927 | Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer |
| Q99240956 | Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma |
| Q40584154 | The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma |
| Q89429151 | Toxicities and outcomes: Do steroids matter? |
| Q92512955 | Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review |
| Q52681592 | Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q33607108 | Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis |
Search more.